RBC Capital has increased its price target for Amgen from $400 to $430, reflecting strong confidence in the biopharmaceutical company's future performance. Amgen's stock has outperformed both the S&P 500 and the broader medical sector recently, supported by expected growth in quarterly earnings per share and revenue. Analysts forecast Amgen's EPS to rise to $5.69 next quarter and revenue to reach $9.91 billion, signaling positive financial momentum. The Outperform rating and higher price target indicate expectations that Amgen will continue to deliver solid returns relative to the market.
As of Oct 08, 2026 20:51 WIB, Amgen (AMGN) trades at USD 408.43 on Pluang, showing a 1-day decline of 1.13%. Despite RBC Capital's raised price target to $430, the stock's market cap stands at $223.32 billion with a dividend yield of 2.44%. Pluang investors currently favor buying, with 81% of order activity on the buy side.
